World CDx 2026 has ended. This guide stays up as the record of who was there. Next: World CDx 2027, Aug 30 – Sep 2, 2027 in Boston
Digital pathology and spatial biomarkers at World CDx 2026
Oct 5–8, 2026 Boston, MA ~900 attendees Website
30 organizations at World CDx 2026 present work in digital pathology & spatial biomarkers: 18 technology and service providers, 8 drug developers and 4 academic, government and non-profit bodies. Between them they bring 44 presentations to the program. Most represented: Merck (4 on the program), Bristol Myers Squibb (3 on the program), GSK (3 on the program). As of Oct 8, 2026.
Format
Top represented
Showing 1–13 of 30 organizations
| Organization | World CDx 2026 Attendance |
|---|---|
Merck Rahway, NJ | |
US pharmaceutical company, known as MSD outside the US and Canada, with oncology medicines including pembrolizumab. | Panel Tue Oct 6 12:30pm Companion Diagnostics from Biomarker Discovery to Global Launch: Building Better Partnerships Across Science, Regulation, & Commercialization Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access Talk Tue Oct 6 2:30pm Integrating Science & Strategy to Advance Companion Diagnostic Development for Optimal Patient Treatment Clinical & companion diagnostic development Panel Wed Oct 7 12:50pm Transforming Patient Enrolment & Monitoring Through Innovation in Liquid Biopsy Analytes, Detection Sensitivity & Data Interpretation Liquid biopsy & MRD Panel Wed Oct 7 3:10pm Advancing Regulatory Frameworks & Standards for Compliant Digital Pathology Co-Development Digital pathology & spatial biomarkersClinical & companion diagnostic development Talk Thu Oct 8 12:20pm A Single-Cell Platform for Linking CRISPR-Edited Variants to Transcriptional Outcomes Biomarker discovery & translation Talk Thu Oct 8 12:20pm Drug Diagnostic Co-Development: Overlooked Challenges & Mitigations Clinical & companion diagnostic development |
Bristol Myers Squibb Princeton, NJ | |
Global pharmaceutical company with medicines in oncology, hematology, immunology and cardiovascular disease. | Panel Tue Oct 6 6:10pm Strengthening Tumor‑Informed MRD Assays with Standardized Analytical Validation to Ensure Reliable Detection & Confident Clinical Interpretation Liquid biopsy & MRDClinical & companion diagnostic development Panel Wed Oct 7 2:10pm Beyond IHC Scoring: Unlocking Next-Generation Clinical Biomarkers through AI-Powered Computational Pathology Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine Panel Wed Oct 7 3:10pm Bolstering Scalable Commercial Drug-Diagnostic Strategies to Ensure Equitable Solutions for Global Precision Oncology Applications Drug–diagnostic commercialization & access Panel Thu Oct 8 9:00am Mobilizing Precision Cancer Care Through the Precision Cancer Consortium to Standardize Testing Pathways & Reduce Access Barriers Drug–diagnostic commercialization & access |
GSK London, UK | |
Global biopharmaceutical company developing vaccines and specialty medicines in infectious disease, HIV, respiratory, immunology and oncology. | Panel Tue Oct 6 6:10pm Strengthening Tumor‑Informed MRD Assays with Standardized Analytical Validation to Ensure Reliable Detection & Confident Clinical Interpretation Liquid biopsy & MRDClinical & companion diagnostic development Panel Wed Oct 7 9:00am Applying AI & Advanced Data Analytics to Transform Biomarker Discovery & Clinical Trial Strategy for Improved Precision Medicine Programs Multimodal & AI-enabled precision medicineBiomarker discovery & translation Panel Wed Oct 7 12:10pm Building the Clinical & Commercial Ecosystem for AI-Enabled Precision Pathology Digital pathology & spatial biomarkersDrug–diagnostic commercialization & access Talk Thu Oct 8 9:50am When a Drug Program Expects Multiple Global Dx Partners: Considerations for Master CDx Agreements Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access |
Caris Life Sciences Irving, TX | ◇Expertise Partner |
Molecular profiling company using whole-exome and whole-transcriptome sequencing plus AI on a large clinico-genomic database for therapy selection and drug development. | Panel Tue Oct 6 5:10pm The Role of AI in the Future of Companion Diagnostics Multimodal & AI-enabled precision medicineClinical & companion diagnostic development Panel Wed Oct 7 11:20am Beyond the Slide: Tissue AI as the Anchor for Multimodal Biomarker Discovery & Global Deployment Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine |
Pfizer New York, NY | |
Global pharmaceutical company with medicines and vaccines across many areas, including oncology drugs such as antibody-drug conjugates. | Panel Wed Oct 7 2:10pm Beyond IHC Scoring: Unlocking Next-Generation Clinical Biomarkers through AI-Powered Computational Pathology Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine Panel Wed Oct 7 3:10pm Innovating Global Rx-Dx Trial Pathways Through Strategic & Compliant Co-Development Partnerships to Deliver Harmonized Precision Medicine Solutions Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access |
CellCarta Montreal, Canada | ◇Program Partner |
Specialty laboratory CRO offering immunology, histopathology, proteomics and genomics testing and sample management for biomarker work in global clinical trials. | Chair Tue Oct 6 2:00pm Chair’s Opening Afternoon Remarks Panel Wed Oct 7 11:20am Beyond the Slide: Tissue AI as the Anchor for Multimodal Biomarker Discovery & Global Deployment Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine Talk Wed Oct 7 12:10pm The CDx Model Needs to Change – What China Taught Us About Breaking Silos, Moving Faster, & Going Global Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access Talk Thu Oct 8 11:00am Can AI Predict ADC Response? Multimodal & AI-enabled precision medicineBiomarker discovery & translation |
Gilead Sciences Foster City, CA | |
Biopharmaceutical company with marketed medicines in HIV, liver disease, oncology and inflammation, including antibody-drug conjugates and CAR T therapies. | Panel Wed Oct 7 11:20am Beyond the Slide: Tissue AI as the Anchor for Multimodal Biomarker Discovery & Global Deployment Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine Panel Wed Oct 7 2:10pm Beyond IHC Scoring: Unlocking Next-Generation Clinical Biomarkers through AI-Powered Computational Pathology Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine Talk Wed Oct 7 2:40pm Promise & Pitfalls of Tumor Target Quantification in Antibody-Drug Conjugate & Immune Cell Engager Drug Development Biomarker discovery & translationDigital pathology & spatial biomarkers |
Pyxis Oncology Boston, MA | |
Clinical-stage oncology biotech developing antibody-drug conjugates, led by micvotabart pelidotin, an ADC targeting extradomain-B of fibronectin in the tumor matrix. | Panel Wed Oct 7 3:10pm Navigating Biomarker Complexity as a Biotech to Build Smarter Precision Oncology Strategies that Maximize Clinical & Commercial Impact Biomarker discovery & translationDrug–diagnostic commercialization & access Talk Thu Oct 8 1:40pm Assessing Histologic Biomarkers of Response to Micvotabart Pelidotin (MICVO), the First-in-Class ADC Targeting the Tumor Extracellular Matrix Protein Extradomain-B of Fibronectin Biomarker discovery & translationDigital pathology & spatial biomarkers |
Bioptimus Paris, France | ◇Program Partner |
Builds AI foundation models of biology, including H-Optimus for histology images and the multimodal M-Optimus model, used in research and drug discovery. | Talk Wed Oct 7 2:10pm From Spatial Atlases to Predictive Insights: Scaling Precision Medicine with the M-Optimus World Model Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine |
◇Panel Partner | |
Regulatory, clinical and quality consultancy for in vitro diagnostics and medical devices, focused on companion diagnostics and digital pathology, with US and UK teams. | Panel Wed Oct 7 3:10pm Advancing Regulatory Frameworks & Standards for Compliant Digital Pathology Co-Development Digital pathology & spatial biomarkersClinical & companion diagnostic development |
◇Spotlight Partner | |
Spatial biology and tissue biomarker services company using AI-based image analysis and pathologist consultation to support drug development and diagnostics. | Talk Wed Oct 7 12:40pm Mapping B-Cell States in Autoimmunity & Cancer: Finding Clinically Adoptable Spatial Biomarkers to Accelerate Precision Medicine Digital pathology & spatial biomarkersBiomarker discovery & translation |
Imagene AI Tel Aviv, Israel | ◇Panel Partner |
Builds AI pathology models and real-world data tools that predict cancer biomarkers from tissue images, including the LungOI lung cancer test. | Panel Wed Oct 7 3:10pm Realizing the Promise, Gaps & Platform Innovation for Precision Medicine at Scale from Global Technology Leaders Multimodal & AI-enabled precision medicine |
Lunit Seoul, South Korea | ◇Program Partner |
South Korean medical AI company with software for cancer screening images and AI analysis of tumor tissue biomarkers. | Talk Thu Oct 8 11:00am Can AI Predict ADC Response? Multimodal & AI-enabled precision medicineBiomarker discovery & translation |
Instantly find 20 buyers in digital pathology & spatial biomarkers
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse World CDx 2026 by
Organization type
Topic
Everyone
Not affiliated with or endorsed by World CDx or its organizers. Submit a correction